In recent years, cancer immunotherapy has become one of the most promising areas of cancer treatment, with immune checkpoint inhibitors, CAR T-cell therapies, and other immuno-oncological strategies transforming the landscape of oncology. However, despite significant progress, many cancers remain resistant to these treatments, and therapeutic responses can be highly variable. A growing area of research in immuno-oncology is the potential role of tertiary lymphoid structures (TLS) in mediating anti-tumor immunity. These ectopic lymphoid-like structures, which develop in chronically inflamed tissues, are being recognized as key players in tumor immune surveillance. In this article, we will explore the concept of TLS, their relationship with cancer, and how targeting these structures could offer novel therapeutic avenues for cancer treatment.
What are Tertiary Lymphoid Structures?
Tertiary lymphoid structures (TLS) are ectopic aggregates of immune cells that resemble lymph nodes or spleen tissue but form in non-lymphoid organs, typically in response to chronic inflammation or persistent infections. Unlike primary lymphoid organs such as the thymus and bone marrow, TLS develop in peripheral tissues that are not part of the immune system’s “mainstream.” These structures can contain specialized immune cell types, including T cells, B cells, dendritic cells, and follicular dendritic cells, creating a microenvironment conducive to adaptive immune responses.
TLS are often found in tissues affected by chronic inflammatory conditions such as autoimmune diseases, infections, and cancer. In the context of tumors, TLS have been shown to play a critical role in shaping the local immune response and influencing tumor progression. Their presence can correlate with improved patient outcomes in various cancers, as they may serve as sites for the activation and proliferation of anti-tumor immune cells. Understanding the mechanisms behind the formation and function of TLS is therefore crucial for developing targeted cancer therapies.
Also Read:
TLS and Cancer: A Double-Edged Sword
The presence of TLS within tumors has been linked to both favorable and unfavorable outcomes, depending on the context. On one hand, TLS can foster anti-tumor immunity by facilitating the recruitment and activation of immune cells that can attack and eliminate cancer cells. Studies have demonstrated that TLS are associated with increased infiltration of cytotoxic T cells, which are capable of recognizing and killing cancer cells. Moreover, the presence of TLS can support the generation of antibodies against tumor antigens through the activation of B cells and the formation of germinal centers within the structure.
On the other hand, TLS can also serve as a sanctuary for immunosuppressive cells, such as regulatory T cells (Tregs), which may dampen the overall immune response. The tumor microenvironment is notoriously immunosuppressive, and TLS can sometimes exacerbate this by harboring these regulatory cells. Furthermore, the interactions between TLS and tumor-associated macrophages (TAMs) can promote tumor progression and resistance to therapy, especially in cancers that have an established immune tolerance.
Thus, TLS can act as a double-edged sword—either supporting anti-tumor immunity or contributing to immune evasion, depending on their composition and the signals they receive from the tumor microenvironment.
Targeting TLS for Cancer Treatment
Given the complexity of TLS in cancer, the idea of therapeutically targeting these structures is gaining traction. Approaches to modulate TLS activity in the tumor microenvironment could enhance the immune response against cancer and improve the efficacy of existing immunotherapies. Several strategies are being explored:
1. Enhancing TLS Formation:
One promising approach is to promote the formation and maturation of TLS within tumors. By creating an environment that encourages TLS development, it may be possible to recruit more immune cells to the site of the tumor and strengthen the local immune response. This could involve the use of cytokines or immune modulators that stimulate the formation of these structures, such as IL-17, lymphotoxin-beta, or other factors that promote lymphoid neogenesis.
Studies have shown that certain therapies can induce TLS formation in tumors. For example, the use of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, has been linked to increased TLS development in some cancers. The goal would be to combine such treatments with therapies that further promote TLS stability and functionality, creating a supportive microenvironment for effective anti-tumor immunity.
2. Targeting TLS-Associated Immunosuppressive Cells:
In tumors where TLS are present but are immunosuppressive, the focus may shift to targeting the cells that inhibit the immune response, such as Tregs and TAMs. These cells can prevent the activation of anti-tumor immune responses and are often recruited to TLS by the tumor. Therapeutic strategies could include targeting these immunosuppressive populations with specific antibodies or small molecules to reverse the inhibitory effects and enhance the activity of cytotoxic T cells.
For instance, targeting Tregs within TLS using monoclonal antibodies against specific surface markers (e.g., CD25 or FoxP3) could help alleviate immune suppression and promote a more robust anti-tumor immune response. Similarly, modulating the activity of TAMs through targeted therapies could disrupt the immune-evasive microenvironment within TLS and promote anti-tumor immunity.
3. Manipulating TLS Composition:
Another approach is to influence the composition of immune cells within TLS. By selectively promoting the accumulation of pro-inflammatory cells, such as CD8+ T cells or dendritic cells, and reducing the presence of immunosuppressive cells, therapies could reprogram TLS to become more effective at combating cancer. For example, adopting strategies to increase the recruitment of dendritic cells to TLS could improve antigen presentation and stimulate a more potent T cell response.
The development of small molecules or biologics that influence the recruitment of specific immune cells to TLS is an exciting area of research. These therapies could be designed to modulate the chemokine and cytokine networks that govern immune cell trafficking, specifically directing the infiltration of effector cells that can target and kill cancer cells.
4. Combining TLS Targeting with Existing Immunotherapies:
TLS-targeting strategies could also be combined with existing cancer immunotherapies, such as immune checkpoint inhibitors, CAR T-cell therapy, or cancer vaccines. Immune checkpoint inhibitors, which block the PD-1/PD-L1 pathway or CTLA-4, have been shown to promote the formation of TLS in some cancers. By combining these therapies with agents that enhance TLS stability or target the immunosuppressive cells within TLS, it may be possible to achieve synergistic effects and improve overall therapeutic efficacy.
Conclusion
The emerging role of tertiary lymphoid structures in cancer offers a new and exciting avenue for cancer immunotherapy. While TLS can act as both allies and obstacles in the fight against cancer, strategically targeting these structures may help unlock their full potential to enhance anti-tumor immunity. From promoting TLS formation and modulating their composition to targeting immunosuppressive cells, the therapeutic manipulation of TLS holds promise for improving cancer treatment outcomes. As our understanding of TLS biology continues to evolve, it is likely that these immune niches will become an integral part of the next generation of cancer therapies, offering new hope for patients battling this devastating disease.
